Case Report

Concurrent Primary Hyperparathyroidism and Humoral Hypercalcemia of Malignancy in a Patient with Clear Cell Endometrial Cancer

Authors: Daniel S. Richey, DO, Brian J. Welch, MD

Abstract

A 65-year-old Caucasian woman with a known history of clear cell endometrial cancer presented with hypercalcemia. Further evaluation demonstrated that the patient had primary hyperparathyroidism due to a parathyroid adenoma, as well as an increased parathyroid hormone-related peptide secondary to her malignancy. To the best of our knowledge, this is the first reported case of a female patient with concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy. This case illustrates the importance of considering a broad differential when evaluating patients with hypercalcemia. It also emphasizes the importance of recognizing the biochemical interplay between parathyroid hormone and parathyroid hormone-related peptide.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Walls J, Ratcliffe WA, Howell A, et al. Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcemia in two hospital populations. Clin Endocrinol (Oxf) 1994;41:407–413.
 
2. Gallacher SJ, Fraser WD, Farquharson MA, et al. Coincidental occurrence of primary hyperparathyroidism and cancer-associated hypercalcemia in a middle-aged man. Clin Endocrinol (Oxf)1993;38:433–437.
 
3. Farr HW, Fahey TJ Jr, Nash AG, et al. Primary hyperparathyroidism and cancer. Am J Surg1973;126:539–543.
 
4. Skrabanek P, McPartlin J, Powell D. Tumor hypercalcemia and “ectopic hyperparathyroidism.”Medicine (Baltimore) 1980;59:262–282.
 
5. Logue FC, Perry B, Chapman RS, et al. A two-site immunoradiometric assay for PTH (1–84) using N and C terminal specific monoclonal antibodies. Ann Clin Biochem 1991;28(pt 2):160–166.
 
6. Ratcliffe WA, Hutchesson AC, Bundred NJ, et al. Role of assays of parathyroid-hormone-related protein in investigation of hypercalcemia. Lancet 1992;339:164–167.
 
7. Bergenfelz A, Norden NE, Ahren B. Intraoperative fall in plasma levels of intact parathyroid hormone after removal of one enlarged parathyroid gland in hyperparathyroid patients. Eur J Surg 1991;157:109–112.
 
8. Schweitzer DH, Hamdy NA, Frolich M, et al. Malignancy-associated hypercalcemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. Clin Endocrinol (Oxf) 1994;41:251–256.
 
9. Audran M, Minebois-Villegas A, Lortholary A, et al. Contribution of parathyroid horomone-related peptide to the evaluation of hypercalcemia. Rev Rhum Engl Ed 1995;62:189–196.
 
10. Budayr AA, Nissenson RA, Klein RF, et al. Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med 1989;111:807–812.
 
11. Schilling T, Pecherstorfer M, Blind E, et al. Parathyroid hormone-related protein (PTHrp) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy. J Clin Endocrinol Metab1993;76:801–803.
 
12. Endres DB, Villanueva R, Sharp CF Jr, et al. Measurement of parathyroid hormone. Endocrinol Metab Clin North Am 1989;18:611–629.
 
13. Syed MA, Horwitz MJ, Tedesco MB, et al. Parathyroid hormone-related protein (1–36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 2001;86:1525–1531.